

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM418457

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Barclays Bank PLC		03/02/2017	Public Limited Company: UNITED KINGDOM
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Coria Laboratories, Ltd.		
<b>Street Address:</b>	400 Somerset Corporate Blvd.		
<b>City:</b>	Bridgewater		
<b>State/Country:</b>	NEW JERSEY		
<b>Postal Code:</b>	08807		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 17</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4937981	SKIN LOVES CERAVE	
<b>Registration Number:</b>	3881852	1 HOUR PIMPLE PATCH	
<b>Registration Number:</b>	3555641	ACNE FREE	
<b>Registration Number:</b>	3773694	ACNE FREE CLEAR SKIN TREATMENTS	
<b>Registration Number:</b>	3641445	ACNE FREE SEVERE SYSTEM	
<b>Registration Number:</b>	4099516	CLEAR 2 GO	
<b>Registration Number:</b>	4119401	KILLER FOAM	
<b>Registration Number:</b>	3204654	REGENETRESSE	
<b>Registration Number:</b>	1034597	AMBI	
<b>Registration Number:</b>	1135419	AMBI	
<b>Registration Number:</b>	0903176	AMBI	
<b>Registration Number:</b>	4131992		
<b>Registration Number:</b>	3760599	EVEN & CLEAR	
<b>Registration Number:</b>	3567633	SOFT & EVEN	
<b>Registration Number:</b>	4321378		
<b>Registration Number:</b>	4321377		
<b>Registration Number:</b>	1898493	AMBI 10	
<b>CORRESPONDENCE DATA</b>			
<b>TRADEMARK</b>			

OP \$440.00 4937981

**Fax Number:** 80091442

***Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***

**Phone:** 614-280-3568

**Email:** John.Salvage@wolterskluwer.com

**Correspondent Name:** CT Corporation System

**Address Line 1:** 4400 Easton Commons Way

**Address Line 2:** Suite 125

**Address Line 4:** Columbus, OHIO 43219

<b>NAME OF SUBMITTER:</b>	Elaine Carrera
---------------------------	----------------

<b>SIGNATURE:</b>	/Elaine Carrera/
-------------------	------------------

<b>DATE SIGNED:</b>	03/06/2017
---------------------	------------

**Total Attachments: 7**

source=3#page1.tif

source=3#page2.tif

source=3#page3.tif

source=3#page4.tif

source=3#page5.tif

source=3#page6.tif

source=3#page7.tif

## RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS

This RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS (this "Release") is entered into as of March 2, 2017 by Barclays Bank PLC, a public limited company with offices located at 745 Seventh Avenue, New York, New York 10019, as Collateral Agent for the Secured Parties (the "Assignor"), in favor of Coria Laboratories, Ltd., a Delaware corporation with offices located at 400 Somerset Corporate Blvd., Bridgewater, New Jersey 08807, Valeant Pharmaceuticals International, Inc., a Canada corporation with offices located at 2150 St. Elzear Blvd. West, Laval, Quebec H7L 4A8 Canada, Valeant Holdings Ireland (formerly Valeant International Bermuda) an Ireland corporation with offices located at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland, and Valeant Pharmaceuticals Luxembourg S.A.R.L., a Luxembourg societe a responsabilite limitee with offices located at 13-15 Avenue de la Liberte, L-1931 Luxembourg, (the "Assignees"). Capitalized terms used in this Release but not defined herein shall have the respective meanings ascribed to such terms in the Pledge and Security Agreement or Trademark Security Agreement (each as defined below), as applicable.

**WHEREAS**, reference is made to (i) that certain Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012, as amended by Amendment No. 1, dated as of March 6, 2012, by Amendment No. 2, dated as of September 10, 2012, by Amendment No. 3, dated as of January 24, 2013, by Amendment No. 4, dated as of February 21, 2013, by Amendment No. 5, dated as of June 6, 2013, by Amendment No. 6, dated as of June 26, 2013, by Amendment No. 7, dated as of September 17, 2013, by Amendment No. 8, dated as of December 20, 2013 by the Successor Agent Agreement, Amendment No. 9, dated as of January 8, 2015, Amendment No. 10, dated as of March 5, 2015, Amendment No. 11, dated as of May 29, 2015, by Amendment No. 12 and Waiver, dated as of April 11, 2016, by Amendment No. 13, dated as of August 23, 2016, and as further supplemented by the Joinder Agreements, dated as of June 14, 2012, July 9, 2012, September 11, 2012, October 2, 2012, December 11, 2012, each of the Joinder Agreements dated as of August 5, 2013, and each of the Joinder Agreements dated as of February 6, 2014, by the Joinder Agreements, each dated as of January 22, 2015 and by the Joinder Agreements, each dated as of April 1, 2015 (as it may be amended, restated, replaced, supplemented or otherwise modified from time to time, the "Credit Agreement") among Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia ("VPII"), certain subsidiaries of VPII, as guarantors, the lenders from time to time party thereto, the Assignor and the others party thereto; (ii) that certain Pledge and Security Agreement, dated as of June 29, 2011, as amended by the Amended and Restated Pledge and Security Agreement, dated as of October 20, 2011, and as further amended by the Second Amended and Restated Pledge and Security Agreement, dated as of February 13, 2012 (as it may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Pledge and Security Agreement"), between the Assignees and the other grantors party thereto and the Assignor; and (iii) that certain Trademark Security Agreement, dated as of July 18, 2016 between the Assignor (as collateral agent) and the Assignees and other grantors party thereto (the "Trademark Security Agreement");

**WHEREAS**, pursuant to the terms and conditions of the Trademark Security Agreement, the Assignees granted to the Assignor, for the benefit of the Secured Parties, a security interest in

and continuing lien on all of the Assignees' right, title and interest in, to and under the following, in each case whether then owned or thereafter acquired by the Assignees or in which the Assignees then had or thereafter acquired any right, title or interest and wherever the same may be located (collectively, the "Trademark Collateral"):

all United States and foreign trademarks, trade names, trade dress, corporate names, company names, business names, fictitious business names, Internet domain names, service marks, certification marks, collective marks, logos, other source or business identifiers, designs and general intangibles of a like nature, whether or not registered, and with respect to any and all of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications listed in Schedule A attached to the Trademark Security Agreement, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds of the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto, and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world;

**WHEREAS**, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on July 18, 2016 at Reel 5836, Frame 0399;

**WHEREAS**, pursuant to that certain Officer's Certificate dated as of March 2, 2017 (the "Certificate"), VPII certified to the Assignor that the Assignees sold the trademarks set forth on Schedule I hereto (the "Specified Trademarks"), which sale has been consummated by the Assignees and the purchaser as of March 2, 2017, as provided in the Certificate; and

**WHEREAS**, the Assignor, solely in reliance on the representations, warranties and certifications made pursuant to the Certificate and without independent investigation, has agreed to terminate and release its security interest solely in the Specified Trademarks and Specified Trademark Collateral (as defined below) related thereto.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Assignor hereby terminates, releases and discharges fully, without representation, warranty or recourse, its security interest in and continuing lien on all of the Assignees' right, title and interest in, to and under (i) the Specified Trademarks, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, (iv) the right to sue or otherwise recover for any past, present and future infringement, dilution or other violation of any of the foregoing or for any injury to the related goodwill, (v) all Proceeds or the foregoing, including, without limitation, license fees, royalties, income, payments, claims, damages and proceeds of suit then or thereafter due and/or payable with respect thereto (but excluding, for the avoidance of doubt, Proceeds from the sale by the Assignees of the Specified Trademarks as referenced in the Certificate), and (vi) all other rights of any kind accruing thereunder or pertaining thereto throughout the world (collectively, the "Specified Trademark Collateral").

The Assignor hereby authorizes the Assignees or the Assignees' authorized representative to record this Release with the United States Patent and Trademark Office.

The Assignor shall execute and deliver any and all documents or other instruments reasonably requested by the Assignees, and at the Assignees' sole cost and expense, to more fully and effectively effectuate the purposes of this Release.


For the avoidance of any doubt, this Release is strictly limited solely and only to the Specified Trademark Collateral and to no other Trademark Collateral. The Assignor continues to maintain, without interruption or impairment, its security interest in all of the Assignees' right, title and interest in, to and under all Trademark Collateral other than the Specified Trademark Collateral. The provisions of the Trademark Security Agreement and the Pledge and Security Agreement shall, except as modified by this Release, continue in full force and effect.

**THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES  
HEREUNDER SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED AND  
ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK  
WITHOUT REGARD TO CONFLICT OF LAWS PRINCIPLES THEREOF.**

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the Assignor has caused this Release to be executed and delivered by its duly authorized officer as of the date first set forth above.

BARCLAYS BANK PLC,  
as Collateral Agent

By: 

Name: **Sean Duggan**  
Title: **Assistant Vice President**

**SCHEDULE I**  
to  
**RELEASE OF SECURITY INTEREST IN SPECIFIED TRADEMARKS**

Specified Trademarks

Current Registered Owner	Mark	App. No.	Reg. No.	App. Date	Reg. Date
Coria Laboratories, Ltd.	SKIN LOVES CERAVE	86510339	4937981	01/21/2015	04/12/2016
Valeant Pharmaceuticals International, Inc.	1 HOUR PIMPLE PATCH	77895183	3881852	12/16/2009	11/23/2010
Valeant Pharmaceuticals International, Inc.	ACNE FREE	76529327	3555641	07/14/2003	01/06/2009
Valeant Pharmaceuticals International, Inc.	ACNE FREE CLEAR SKIN TREATMENTS	77538297	3773694	08/04/2008	04/06/2010
Valeant Pharmaceuticals International, Inc.	ACNE FREE SEVERE SYSTEM	77531014	3641445	07/24/2008	06/16/2009
Valeant Pharmaceuticals International, Inc.	CLEAR 2-GO	77895178	4099516	12/16/2009	02/14/2012
Valeant Pharmaceuticals International, Inc.	KILLER FOAM	85199951	4119401	12/16/2010	03/27/2012
Valeant Pharmaceuticals International, Inc.	REGENETRESSE	78717923	3204654	09/21/2005	01/30/2007
Valeant Holdings Ireland [formerly Valeant International Bermuda]	AMBI	73038742	1034597	12/05/1974	03/02/1976
Valeant Holdings Ireland [formerly Valeant International Bermuda]	AMBI	73201119	1135419	01/23/1979	05/20/1980
Valeant Holdings Ireland [formerly Valeant International Bermuda]	AMBI	72287261	0903176	12/20/1967	11/24/1970
Valeant Pharmaceuticals Luxembourg SARL	AMBI DIAMOND LOGO (BLACK/WHITE)	85413996	4131992	09/02/2011	04/24/2012
Valeant Pharmaceuticals Luxembourg SARL	EVEN & CLEAR	77787609	3760599	07/23/2009	03/16/2010
Valeant Pharmaceuticals Luxembourg SARL	SOFT & EVEN	77510838	3567633	06/30/2008	01/27/2009
Valeant Pharmaceuticals Luxembourg SARL	AMBI DIAMOND LOGO (BLACK/WHITE)	85090715	4321378	07/22/2010	04/16/2013
Valeant Pharmaceuticals Luxembourg SARL	AMBI DIAMOND LOGO (COLOR)	85090712	4321377	07/22/2010	04/16/2013
Valeant Holdings Ireland [formerly Valeant International Bermuda]	AMBI 10	74520827	1898493	05/09/1994	06/13/1995